Soorki Maryam Naderi
Department of Biology, School of Science, Shahid Chamran University of Ahvaz, Ahvaz, Iran.
Toxicon. 2025 Feb;255:108229. doi: 10.1016/j.toxicon.2025.108229. Epub 2025 Jan 7.
SARS-CoV-2 is from the enveloped virus family responsible for the COVID-19 pandemic. No efficient drugs are currently available to treat infection explicitly caused by this virus. Therefore, searching for effective treatments for severe illness caused by SARS-CoV-2 is crucial. Scorpion venoms are significant sources of peptides with pharmaceutical potential, including antivirals. Although some studies have determined the antiviral effects of some scorpion peptides on other members of the Coronaviridae family, a few anti-SARS-CoV-2 effects of these peptides have been reported until now. This study assessed the antiviral effects of five predicted antimicrobial peptides with potential for antiviral activities from the Iranian yellow scorpion "Odontobuthus doriae" by computational methods. These peptides were selected from the cDNA library that our research team constructed. A 3D model of peptides was designed with I-TASSER. The models were refined using a 200 ns Molecular Dynamics (MD) simulation using Gromacs 2021.2 software. Refined models were Docked with the RBD domain of SARS-CoV-2 spike protein using HADDOCK software. The docking of human ACE2 peptide with the RBD domain was also assessed. The docked complexes (RBD-peptide and RBD-ACE2) were refined again by a 100 ns MD simulation and then analyzed. The results from molecular docking after molecular dynamics simulation showed that ODAMP2 and ODAMP5 after stabilizing analysis and according to MMPBSA results (with -59.24 kcal/mol and -51.82 kcal/mol, respectively) have a strong binding affinity to the RBD domain of COVID-19 spike protein compared to human ACE2 and some other studied components. Therefore, this peptide can be an excellent candidate for use as an agent to inhibit the RBD domain of SARS-COV2 virus in clinical studies for medicinal purposes after in vitro and in vivo laboratory evaluations.
严重急性呼吸综合征冠状病毒2(SARS-CoV-2)属于有包膜病毒家族,是导致新冠疫情的病原体。目前尚无有效药物可专门治疗由该病毒引起的感染。因此,寻找针对SARS-CoV-2所致重症的有效治疗方法至关重要。蝎毒是具有药物潜力的肽的重要来源,包括抗病毒肽。尽管一些研究已确定某些蝎肽对冠状病毒科其他成员的抗病毒作用,但迄今为止,关于这些肽对SARS-CoV-2的抗病毒作用报道较少。本研究通过计算方法评估了来自伊朗黄蝎“奥氏异蝎”的五种具有抗病毒活性潜力的预测抗菌肽的抗病毒作用。这些肽是从我们研究团队构建的cDNA文库中筛选出来的。使用I-TASSER设计肽的三维模型。使用Gromacs 2021.2软件通过200纳秒分子动力学(MD)模拟对模型进行优化。使用HADDOCK软件将优化后的模型与SARS-CoV-2刺突蛋白的受体结合域(RBD)进行对接。还评估了人血管紧张素转换酶2(ACE2)肽与RBD结构域的对接情况。对接复合物(RBD-肽和RBD-ACE2)通过100纳秒MD模拟再次优化,然后进行分析。分子动力学模拟后的分子对接结果表明,经过稳定性分析后,根据分子力学/泊松-玻尔兹曼表面积(MMPBSA)结果(分别为-59.24千卡/摩尔和-51.82千卡/摩尔),与人类ACE2和其他一些研究成分相比,ODAMP2和ODAMP5对新冠病毒刺突蛋白的RBD结构域具有很强的结合亲和力。因此,在体外和体内实验室评估后,这种肽可作为一种在医学临床研究中抑制SARS-COV2病毒RBD结构域的药物极佳候选物。